A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Phase 1

Terminated

• Conditions: Platinum-resistant Ovarian Cancer
• Interventions: Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

• Registration Number: NCT04718376
• Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Brief Summary

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.

Detailed Description

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer. At least 30 subjects will be recruited in this study. The subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1 cycle). All patients will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles). Delays in drug administration is allowed from the cycle 2, however, the delays should be no more than 3 weeks. Dose adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.

Study Timeline

• Study First Submitted: 2020-12-14
• Study Start: 2021-01-12
• Study First Submitted QC: 2021-01-20
• Study First Posted: 2021-01-22
• Status Verified: 2021-05
• Primary Completion: 2023-05-22
• Study Completion: 2023-05-22
• Last Update Submitted: 2024-03-05
• Last Update Posted: 2024-03-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 56

Inclusion Criteria

1. Subjects fully understand and voluntarily participate in this study and sign informed consent;
2. Age ≥18, female;
3. Histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma (excluding low grade serous carcinoma and mucous carcinoma);
4. Fail to respond to or progressed on the standard platinum-based therapy ;
5. At least one measurable lesion according to RECIST v1.1;
6. ECOG performance status of 0 to 2;
7. Life expectancy ≥ 12 weeks;
8. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation);
9. Adequate organ function;
10. Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment;
11. Fully comply with the protocol.

Exclusion Criteria

1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;
2. Untreated or symptomatic central nervous system (CNS) metastases;
3. Pericardial effusion with clinical symptoms
4. History of allotransplantation;
5. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection;
6. Serious infection or interstitial pneumonia within 1 week prior to the first dose administration;
7. Use of other anticancer treatment within 4 weeks prior to the first dose administration;
8. Enrolled in any other clinical trials within 4 weeks prior to the first dose administration;
9. Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period;
10. Thrombosis or thromboembolism within 6 months prior to screening;
11. History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ;
12. Impaired cardiac function or serious cardiac disease;
13. Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2.
14. Pregnant or lactating female;
15. Serious and/or uncontrolled systemic diseases;
16. Not suitable for this study as decided by the investigator due to other reasons.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Mitoxantrone Hydrochloride Liposome Injection	Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)	Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.

Primary Outcome Measures

Name	Time	Method
adverse events (AEs)	from the initiation of the first dose to 28 days after the last dose，assessed up to 36 months	The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).

Secondary Outcome Measures

Name	Time	Method
duration of response (DoR)	From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months	To investigate the preliminary antitumor efficacy
overall survival (OS)	From the enrollment to the death of last subject or the end of the clinical trial (assessed up to 36 months)	To investigate the preliminary antitumor efficacy
overall response rate (ORR)	From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)	To investigate the preliminary antitumor efficacy
duration of complete response (DCR)	From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months	To investigate the preliminary antitumor efficacy
progression-free survival (PFS)	From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months	To investigate the preliminary antitumor efficacy

Trial Locations

Locations (7)

Guangxi Medical University Cancer Hospital; 🇨🇳 Nanning, Guangxi, China

Chongqing University Cancer Hospital; 🇨🇳 Chongqing, Chongqing, China

Harbin Medical University Hospital; 🇨🇳 Harbin, Heilongjiang, China

Guizhou Cancer Hospital; 🇨🇳 Guiyang, Guizhou, China

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China

Fujian Cancer Hospital; 🇨🇳 Fuzhou, Fujian, China